Education
About Us
Working with TipRanks
Follow Us
Huakang Biomedical Holdings Company Limited (HK:8622)
:8622
RESEARCH TOOLSreports
Top Page
Huakang Biomedical Holdings Company Limited
(8622)
52Neutral
Huakang Biomedical Holdings Company Limited (8622) vs. S&P 500 (SPY)
Market Cap
HK$177.67M
Dividend YieldN/A
Average Volume (3M)498.13K
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue Growth1.13%
EPS Growth38.41%
CountryHK
Employees91
SectorHealthcare
Sector Strength65
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding500,472,000
10 Day Avg. Volume493,600
30 Day Avg. Volume498,133
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Huakang Biomedical Holdings Company Limited Business Overview & Revenue Model
Company DescriptionHuakang Biomedical Holdings Company Limited (8622) is a company engaged in the biomedical sector, focusing on the research, development, production, and sale of healthcare products. The company offers a range of products that cater to various health and wellness needs, including biomedical and nutraceutical products.
How the Company Makes MoneyHuakang Biomedical Holdings Company Limited generates revenue primarily through the sale of its healthcare products. The company's revenue streams include direct product sales to consumers and partnerships with retailers and distributors. By leveraging its research and development capabilities, the company continuously innovates its product offerings, which helps maintain a competitive edge in the market. Significant partnerships with healthcare providers and retail chains also contribute to its earnings by facilitating wider distribution and increasing market penetration.
Huakang Biomedical Holdings Company Limited Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 25.08M | 24.63M | 25.33M | 26.13M | 21.97M | 25.47M | Gross Profit |
| 16.54M | 16.09M | 16.91M | 16.46M | 14.72M | 17.89M | EBIT |
| -6.68M | -6.48M | -2.95M | -3.80M | -8.74M | 470.00K | EBITDA |
| -5.35M | -2.55M | 188.00K | -852.00K | -8.10M | 3.49M | Net Income Common Stockholders |
| -6.11M | -5.78M | -3.08M | -4.22M | -11.63M | -284.00K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 48.79M | 32.94M | 33.30M | 36.21M | 41.94M | 48.79M | Total Assets |
| 0.00 | 65.31M | 66.40M | 67.06M | 72.70M | 78.71M | Total Debt |
| 0.00 | 5.14M | 469.00K | 1.68M | 2.64M | 1.61M | Net Debt |
| 48.79M | -27.80M | -32.83M | -34.52M | -39.30M | -47.18M | Total Liabilities |
| 0.00 | 14.30M | 9.88M | 9.36M | 10.84M | 8.03M | Stockholders Equity |
| 70.69M | 51.02M | 56.52M | 57.70M | 61.86M | 70.69M |
| Cash Flow | Free Cash Flow | ||||
| -2.82M | -1.55M | 475.00K | -4.71M | -6.00M | -5.60M | Operating Cash Flow |
| -2.82M | -48.00K | 1.29M | -2.38M | -3.92M | -3.39M | Investing Cash Flow |
| -122.00K | -1.15M | -6.11M | -2.06M | -1.94M | -2.02M | Financing Cash Flow |
| 6.90M | 1.02M | 2.32M | -1.37M | -1.11M | -594.00K |
Huakang Biomedical Holdings Company Limited Technical Analysis
Positive
0.34
Price Trends
0.32
Positive
0.26
Positive
0.22
Positive
Market Momentum
<0.01
Negative
67.28
Neutral
90.80
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8622, the sentiment is Positive. The current price of 0.34 is above the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.32, and above the 200-day MA of 0.22, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 67.28 is Neutral, neither overbought nor oversold. The STOCH value of 90.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8622.
Huakang Biomedical Holdings Company Limited Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$12.43B | 12.56 | 7.50% | 3.20% | -0.38% | 2.07% | |
52 Neutral | HK$177.67M | ― | -7.93% | ― | 1.13% | 38.41% | |
51 Neutral | $5.31B | 3.33 | -39.82% | 2.92% | 17.95% | 1.84% | |
48 Neutral | HK$252.65M | ― | -30.23% | ― | 5.79% | -780.00% | |
48 Neutral | HK$795.76M | 9.46 | 6.29% | ― | -21.48% | -7.50% |
* Healthcare Sector Average
Performance Comparison
HK:8622
Huakang Biomedical Holdings Company Limited
0.35
0.25
250.00%
HK:8081
Hang Tai Yue Group Holdings Ltd.
0.05
>-0.01
-16.67%
HK:6826
Shanghai Haohai Biological Technology Co., Ltd. Class H
24.45
-3.63
-12.93%
HK:6828
Beijing Gas Blue Sky Holdings Ltd
0.03
-0.01
-25.00%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.